

The Office of Research on Women's Health invites individuals and individuals representing organizations with an interest in research areas related to women's health to provide written and oral testimony on the state of knowledge and continuing or emerging gaps in knowledge about women's health across the life span, sex/gender differences and the impact on women's health, new priorities for research on women's health, the environmental, genetic, hormonal, non-hormonal, and other factors that impact women's health, and career issues for women scientists and how to overcome the barriers. Due to time constraints, only one representative from each organization may present oral testimony, with presentations limited to 10 minutes. A letter of intent to present such testimony should be sent by interested individuals and organizations to Ms. Maxine Smith, Houston Associates, 1010 Wayne Avenue, Suite 1200, Silver Spring, MD 20910. Presenters should send three (3) written copies of their testimony, including a brief description of their organization, to the above address no later than May 20, 1997. The date of receipt of the letter will establish the order of presentations at the June meeting.

Individuals and organizations wishing to provide written statements only may send three (3) copies of their statements to the above address by May 20, 1997. All written testimony will be made available to the conferees prior to the June 11 meeting day. Comments and questions related to the June meeting should be addressed to Ms. Smith.

This meeting is the second of three regional public hearings and scientific workshops of similar design to be convened by the Office of Research on Women's Health. At the conclusion of this series of meetings, the Office of Research on Women's Health will convene a national meeting to address the deliberations and recommendations from the regional public hearings and scientific workshops for the purpose of developing a report for priorities for research on women's health for the 21st century.

Dated: April 3, 1997.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 97-9301 Filed 4-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Method of Identifying Persons Susceptible to Autoimmune Neuropsychiatric Disorders

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice its interest in the invention embodied in U.S. Patent Application Serial No. 08/473,033, filed June 6, 1995, entitled, "Method of Identifying Persons Susceptible to Autoimmune Neuropsychiatric Disorders," and subsequent filings, to Callisto Pharmaceuticals, Inc., having a place of business in New York, New York. The United States is a joint assignee of the patent rights in these inventions.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use would be diagnosing persons with, or at risk of developing, certain neuropsychiatric disorders as described in the patent application.

SUPPLEMENTARY INFORMATION: Obsessive compulsive disorder is a severe debilitating condition that can interfere dramatically with daily activities. Obsessive thoughts can include worries about either personal or family safety, past actions, or fears of contamination. Currently there is no known biologic or genetic marker diagnostic for this disorder. However, there is evidence that certain autoimmune diseases have accompanying psychological symptoms including obsessive compulsive behavior, attention deficit hyperactivity disorder, emotional lability, and irritability. The patent application relates to the discovery that in patients at risk for developing neuropsychiatric disorders due to autoimmune disease there is a dramatic increase in the number of B lymphocytes expressing an alloantigen. Detection of the antigen has

been shown to be predictive for obsessive compulsive behavior. In addition, individuals at genetic risk for these neuropsychiatric disorders can also be identified.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Leopold J. Luberecki, Jr., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 20852-3804; Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-0220. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 9, 1997 will be considered.

Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 31, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-9237 Filed 4-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[OR-118-6332-00; GP7-0136]

Closure of All Segments of the London Peak Overlook Trail to Off-Highway and Mechanized Vehicle Use

AGENCY: Bureau of Land Management, Medford District Office.

ACTION: Emergency closure of public land trail in Josephine County, Oregon.

SUMMARY: Notice is hereby given that effective immediately, all segments of the London Peak Overlook Trail under Bureau of Land Management control are closed to all uses other than foot traffic or wheelchairs. The closure is made under the authority of 43 CFR 8341.2. The closure will remain in effect until such time that changes in resource management warrant modifications.

The public lands affected by this emergency closure are specifically identified as follows:

London Peak Overlook Trail on BLM lands in T.33 S., R. 6 W., Section 21, Willamette